Page 5 - Pascal Deschatelets News Today

Needham & Company LLC reiterated their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a research note issued to investors on Thursday, Benzinga reports. They currently have a $60.00 price objective on the stock. A number of other analysts have also commented on APLS. Oppenheimer reissued an outperform rating on shares […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) insider Pascal Deschatelets sold 12,000 shares of Apellis Pharmaceuticals stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $23.66, for a total value of $283,920.00. Following the completion of the sale, the insider now owns 1,053,313 shares of the […]

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective reduced by Raymond James from $156.00 to $89.00 in a research note issued to investors on Tuesday, Benzinga reports. Raymond James currently has a strong-buy rating on the stock. Other equities analysts have also issued research reports about the stock. Citigroup dropped their price target […]

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) released its earnings results on Monday. The company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.35) by $0.33, MarketWatch Earnings reports. Apellis Pharmaceuticals had a negative return on equity of 221.60% and a negative net margin of 356.02%. The business had revenue of $95.00 […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report)’s stock price hit a new 52-week low during trading on Monday . The stock traded as low as $25.88 and last traded at $25.95, with a volume of 8073849 shares trading hands. The stock had previously closed at $32.02. Analysts Set New Price Targets Several equities research […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Investment analysts at Wedbush increased their Q3 2023 earnings estimates for shares of Apellis Pharmaceuticals in a note issued to investors on Thursday, July 20th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of ($1.06) for the quarter, up from their […]

China Universal Asset Management Co. Ltd. grew its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 110.7% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,366 shares of the company’s stock after buying an additional 1,243 shares during the period. China Universal […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) insider Pascal Deschatelets sold 12,000 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, July 10th. The shares were sold at an average price of $84.55, for a total value of $1,014,600.00. Following the completion of the transaction, the insider now owns 1,046,813 shares in the […]

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $94.75 and last traded at $94.12, with a volume of 168048 shares trading hands. The stock had previously closed at $93.31. Wall Street Analysts Forecast Growth A number of […]

Moore Capital Management LP trimmed its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) by 94.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,000 shares of the company’s stock after selling 169,958 shares during the quarter. Moore Capital Management […]